The previous page is sending you to https://zenasbio.com/news/zenas-biopharma-announces-first-patient-dosed-in-phase-3-clinical-study-of-obexelimab-for-the-treatment-of-immunoglobulin-g4-related-disease-igg4-rd/.

 If you do not want to visit that page, you can return to the previous page.